ClinicalTrials.gg
CompletedNCT01243411Updated Oct 5, 2017Results posted

A Study of AA4500 in Men With Peyronie's Disease

A Phase 3 interventional study of AA4500 in Peyronie's Disease, sponsored by Endo Pharmaceuticals. Completed at 39 sites in 9 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-05.

Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
348
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing Microbial Collagenase in Penile Induration — none open to participants now, 3 under way, none of them phase 3. Microbial Collagenase · Penile Induration.

Enrollment
3rd of 13
348 · median 40
Started
2010
with 2 others
Phase 3
4 of 13
none open now
Registered
4th of 13
by date
Lead sponsor
6 of 13
Endo Pharmaceuticals

Among the 13 studies testing Microbial Collagenase in Penile Induration, this one is the 3rd largest by enrollment, is one of 3 that started in 2010, is one of 4 in phase 3, and was the 4th registered.

Penile Induration

48 studies on the registry are indexed under Penile Induration; 10 are open to participants now.

Browse Penile Induration studies →

Open to participants now

None of the 13 studies testing Microbial Collagenase in Penile Induration is open now. The open studies under Penile Induration, anywhere →

About Microbial Collagenase

Microbial Collagenase: first FDA approval 1965 (SANTYL), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 8 Penile Induration studies recruiting now, 5 set no upper age limit and 2 stop at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing Microbial Collagenase in Penile Induration as a file.
02

Study summary

This study is a Phase 3, open-label study of the safety and efficacy of AA4500 0.58 mg in subjects with Peyronie's disease. Subjects will be screened for study eligibility within 21 days before the initial injection of study drug in the first treatment cycle.

After up to four treatment cycles, each subject will be followed for additional safety and efficacy assessments on Days 168 (± 7 days) and 252 (± 7 days) (nominal weeks 24 and 36).

After the final injection of each treatment cycle, the investigator will model the plaque in an attempt to stretch or elongate the plaque. If the subject's penile curvature is reduced to \<15° after the first, second, or third cycle of injections or if the investigator determines further treatment is not clinically indicated (eg, adverse events; allergic reaction), subsequent treatment cycles will not be administered.

Approximately 300 subjects will be enrolled.

03

Conditions studied

  • Peyronie's Disease

Browse trials for

Keywords

  • Peyronie's Disease, penile plaque, penile curvature
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

No subject should be enrolled until all eligibility criteria have been satisfied. Subjects who receive placebo in a previous Auxilium-sponsored study may enroll in this study provided they continue to meet the eligibility requirements. To qualify for the study a subject must:

  1. Be a male and be ≥ 18 years of age
  2. Be in a stable relationship with a female partner/spouse for at least 3 months before screening and be willing to have vaginal intercourse with that partner/spouse
  3. Have symptom(s) of Peyronie's disease for at least 12 months before the first dose of study drug and have evidence of stable disease as determined by the investigator
  4. Have penile curvature of at least 30° in the dorsal, lateral, or dorsal/lateral plane at screening. It must be possible to delineate the single plane of maximal curvature for evaluation during the study
  5. Be judged to be in good health, based upon the results of a medical history, physical examination, and laboratory profile
  6. Voluntarily sign and date an agreement approved by the Institutional Review Board/Independent Ethics Committee (IRB/IEC). The subject must also sign an authorization form to allow disclosure of his protected health information (PHI). The PHI authorization form and informed consent form may be an integrated form or may be separate forms depending on the institution
  7. Be able to read, complete and understand the various rating instruments in English or the appropriate local language for the country in which the study is being performed.

Exclusion criteria

-

Exclusion Criteria:

A subject will be excluded from study participation if he:

  1. Has a penile curvature of less than 30° or greater than 90° at the screening visit
  2. Has any of the following conditions:

    • Chordee in the presence or absence of hypospadias
    • Thrombosis of the dorsal penile artery and/or vein
    • Infiltration by a benign or malignant mass resulting in penile curvature
    • Infiltration by an infectious agent, such as lymphogranuloma venereum
    • Ventral curvature from any cause
    • Presence of an active sexually transmitted disease
    • Known active or C
    • Known immune deficiency disease or be positive for (HIV)
  3. Has previously undergone surgery for Peyronie's disease
  4. Fails to have an erection which in the opinion of the investigator is sufficient to accurately measure the subject's penile deformity after administration of prostaglandin E1 or trimix
  5. Has a calcified plaque as evident by appropriate radiographic evaluation, penile x-ray or penile ultrasound that would prevent proper injection of study medication (penile ultrasound only in EU countries). Non-contiguous stippling of calcium is acceptable for inclusion provided the calcium deposit does not interfere with the injection of AA4500 into the plaque
  6. Has an isolated hourglass deformity of the penis
  7. Has the plaque causing curvature of the penis located proximal to the base of the penis, so that the injection of the local anesthetic would interfere with the injection of AA4500 into the plaque
  8. Has previously received alternative medical therapies for Peyronie's disease administered by the intralesional route (including, but not limited to, , verapamil, and the naturally occurring low molecular weight protein, interferon-α2b) within 3 months before the first dose of study drug or plans to use any of these medical therapies at any time during the study
  9. Has received alternative medical therapies for Peyronie's disease administered by the oral (including, but not limited to, vitamin E [> 500 U], potassium aminobenzoate [Potaba], tamoxifen, colchicine, pentoxifylline, over-the-counter erectile dysfunction medications, or steroidal anti-inflammatory drugs) or topical routes (including, but not limited to, verapamil applied as a cream) within 3 months before the first dose of study drug or plans to use any of these medical therapies at any time during the study
  10. Has had extracorporeal shock wave therapy (ESWT) for the correction of Peyronie's disease within the 6-month period before screening or plans to have ESWT at any time during the study
  11. Has used any mechanical type device for correction of Peyronie's disease within the 2-week period before screening or plans to use any these devices at any time during the study
  12. Has used a mechanical device to induce a passive erection within the 2-week period before screening or plans to use any of these devices at any time during the study
  13. Has significant erectile dysfunction that has failed to respond to oral treatment with phosphodiesterase type 5 (PDE5) inhibitors
  14. Has a penile Duplex Doppler ultrasound evaluation at screening that shows compromised penile hemodynamics that in the opinion of the investigator is
  15. Has uncontrolled hypertension, as determined by the investigator
  16. Has a known recent history of stroke, bleeding, or other significant medical condition, which in the investigator's opinion would make the subject unsuitable for enrollment in the study
  17. Is unwilling or unable to cooperate with the requirements of the study including completion of all scheduled study visits
  18. Has received an drug or treatment within 30 days before the first dose of study drug, except for subjects who receive one treatment cycle of AA4500 in Study AUX-CC-805
  19. Has a known systemic allergy to collagenase or any other of AA4500
  20. Has a known allergy to any concomitant medication required as per the protocol
  21. Has received anticoagulant medication (except for ≤ 165 mg aspirin daily or ≤ 800 mg of over-the-counter NSAIDS daily) during the 7 days before each dose of study drug
  22. Has received any collagenase treatments within 30 days of the first dose of study drug, except for subjects who receive one treatment cycle of AA4500 in Study AUX-CC-805
  23. Has, at any time, received AA4500 for the treatment of Peyronie's disease, except for subjects who receive one treatment cycle of AA4500 in Study AUX-CC-805
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
348 participants (actual)

Study arms

  • Experimental
    AA4500

    collagenase clostridium histolyticum

    Biological: AA4500

Interventions

  • BiologicalAA4500

    2 injections separated by at least 24 hours but not more than 72 hours, repeated after 42 days (± 5 days) for up to 4 treatment cycles (ie, total of up to 8 injections per subject)

    Also known as: XIAFLEX

06

What researchers measure

Primary outcomes

  1. Percentage Change From Baseline in Penile Curvature

    A negative value in the percentage change from baseline in penile curvature deformity (angle measured in degrees) indicates less curvature.

    Time frame: Baseline and Week 36

  2. Change From Baseline in the Peyronie's Disease Bother Domain of the Peyronie's Disease Questionnaire (PDQ)

    Peyronie's disease bother score range 0 (no issue or not at all bothered) to 4 (extremely bothered) on 4 questions; total score range 0 to 16. A decrease in the change from baseline total score in the Peyronie's disease bother domain of the PDQ is indicated by a negative number.

    Time frame: Baseline and Week 36

Secondary outcomes

  1. Change From Baseline in the Severity of Peyronie's Disease Symptoms Domain of the PDQ

    Peyronie's disease symptoms (physical and psychological) severity score range 0 (none) to 4 (very severe) on 6 questions; total score range 0 to 24. A decrease in the change from baseline total score in the Peyronie's disease symptoms domain of the PDQ is indicated by a negative number.

    Time frame: Baseline and Week 36

  2. Change From Baseline in the Penile Pain Domain of the PDQ in Subjects With Baseline Penile Pain Score ≥4

    Penile pain scale range 0 (no pain) to 10 (extreme pain) on 3 questions; total score range 0 to 30. A decrease in the change from baseline total score in the penile pain domain of the PDQ is indicated by a negative number. Subjects were required to have a penile pain score of 4 or greater at baseline.

    Time frame: Baseline and Week 36

  3. A Responder Analysis Based on Subject Overall Global Assessment

    Subject overall global assessment of Peyronie's disease score range -3 (much worse) to 3 (much improved). A score of 1 (improved in a small but important way), 2 (moderately improved), or 3 indicate a responder.

    Time frame: Week 36

  4. Change in the Overall Satisfaction Domain of the International Index of Erectile Function (IIEF)

    Overall satisfaction domain of the IIEF score range 0 to 5 on 2 questions where higher scores indicate improved function or satisfaction; total score range 0 to 10.

    Time frame: Baseline and Week 36

  5. Change From Baseline in Penile Plaque Consistency

    Penile plaque consistency score range 1 (non-palpable) to 5 (hard). A decrease in the change from baseline in penile plaque consistency is indicated by a negative number.

    Time frame: Baseline and Week 36

  6. A Composite Responder Analysis Based on Change From Baseline in Penile Curvature and in the Peyronie's Disease Bother Score

    A composite responder is indicated by * a percent reduction from baseline in penile curvature greater than or equal to the threshold, and * a reduction from baseline in Peyronie's disease bother score greater than or equal to the threshold, or change in the overall sexual activity within the last 3 months to having vaginal intercourse from no vaginal intercourse at screening.

    Time frame: Week 36

  7. Change From Baseline in Penile Length

    A negative value represents a reduction in measurement from baseline.

    Time frame: Baseline and Week 36

07

Results

Posted Apr 15, 2015

Participant flow

Participant flow — Overall Study
MilestoneAA4500
Started347
Completed306
Not completed41
Withdrew: Withdrawal by subject18
Withdrew: Lost to follow-up10
Withdrew: Adverse event5
Withdrew: Other8

Outcome measures

PrimaryPercentage Change From Baseline in Penile Curvature

A negative value in the percentage change from baseline in penile curvature deformity (angle measured in degrees) indicates less curvature.

Time frame:
Baseline and Week 36
Reported as:
Mean · percentage of curvature change
Percentage Change From Baseline in Penile Curvature
percentage of curvature changeAA4500
Percentage Change From Baseline in Penile Curvature-34.4 ± 25.21
PrimaryChange From Baseline in the Peyronie's Disease Bother Domain of the Peyronie's Disease Questionnaire (PDQ)

Peyronie's disease bother score range 0 (no issue or not at all bothered) to 4 (extremely bothered) on 4 questions; total score range 0 to 16. A decrease in the change from baseline total score in the Peyronie's disease bother domain of the PDQ is indicated by a negative number.

Time frame:
Baseline and Week 36
Reported as:
Mean · units on a scale
Change From Baseline in the Peyronie's Disease Bother Domain of the Peyronie's Disease Questionnaire (PDQ)
units on a scaleAA4500
Change From Baseline in the Peyronie's Disease Bother Domain of the Peyronie's Disease Questionnaire (PDQ)-3.3 ± 3.46
SecondaryChange From Baseline in the Severity of Peyronie's Disease Symptoms Domain of the PDQ

Peyronie's disease symptoms (physical and psychological) severity score range 0 (none) to 4 (very severe) on 6 questions; total score range 0 to 24. A decrease in the change from baseline total score in the Peyronie's disease symptoms domain of the PDQ is indicated by a negative number.

Time frame:
Baseline and Week 36
Reported as:
Mean · units on a scale
Change From Baseline in the Severity of Peyronie's Disease Symptoms Domain of the PDQ
units on a scaleAA4500
Change From Baseline in the Severity of Peyronie's Disease Symptoms Domain of the PDQ-4.2 ± 5.14
SecondaryChange From Baseline in the Penile Pain Domain of the PDQ in Subjects With Baseline Penile Pain Score ≥4

Penile pain scale range 0 (no pain) to 10 (extreme pain) on 3 questions; total score range 0 to 30. A decrease in the change from baseline total score in the penile pain domain of the PDQ is indicated by a negative number. Subjects were required to have a penile pain score of 4 or greater at baseline.

Time frame:
Baseline and Week 36
Reported as:
Mean · units on a scale
Change From Baseline in the Penile Pain Domain of the PDQ in Subjects With Baseline Penile Pain Score ≥4
units on a scaleAA4500
Change From Baseline in the Penile Pain Domain of the PDQ in Subjects With Baseline Penile Pain Score ≥4-5.3 ± 4.93
SecondaryA Responder Analysis Based on Subject Overall Global Assessment

Subject overall global assessment of Peyronie's disease score range -3 (much worse) to 3 (much improved). A score of 1 (improved in a small but important way), 2 (moderately improved), or 3 indicate a responder.

Time frame:
Week 36
Reported as:
Number · participants
A Responder Analysis Based on Subject Overall Global Assessment
participantsAA4500
Responder Status - Yes172
Responder Status - No66
SecondaryChange in the Overall Satisfaction Domain of the International Index of Erectile Function (IIEF)

Overall satisfaction domain of the IIEF score range 0 to 5 on 2 questions where higher scores indicate improved function or satisfaction; total score range 0 to 10.

Time frame:
Baseline and Week 36
Reported as:
Mean · units on a scale
Change in the Overall Satisfaction Domain of the International Index of Erectile Function (IIEF)
units on a scaleAA4500
Change in the Overall Satisfaction Domain of the International Index of Erectile Function (IIEF)1.1 ± 2.23
SecondaryChange From Baseline in Penile Plaque Consistency

Penile plaque consistency score range 1 (non-palpable) to 5 (hard). A decrease in the change from baseline in penile plaque consistency is indicated by a negative number.

Time frame:
Baseline and Week 36
Reported as:
Mean · units on a scale
Change From Baseline in Penile Plaque Consistency
units on a scaleAA4500
Change From Baseline in Penile Plaque Consistency-0.8 ± 0.93
SecondaryA Composite Responder Analysis Based on Change From Baseline in Penile Curvature and in the Peyronie's Disease Bother Score

A composite responder is indicated by * a percent reduction from baseline in penile curvature greater than or equal to the threshold, and * a reduction from baseline in Peyronie's disease bother score greater than or equal to the threshold, or change in the overall sexual activity within the last 3 months to having vaginal intercourse from no vaginal intercourse at screening.

Time frame:
Week 36
Reported as:
Number · participants
A Composite Responder Analysis Based on Change From Baseline in Penile Curvature and in the Peyronie's Disease Bother Score
participantsAA4500
Responder - Yes177
Responder - No140
Responder - Missing30
SecondaryChange From Baseline in Penile Length

A negative value represents a reduction in measurement from baseline.

Time frame:
Baseline and Week 36
Reported as:
Mean · centimeters
Change From Baseline in Penile Length
centimetersAA4500
Change From Baseline in Penile Length0.4 ± 1.11

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AA4500—13/347 (3.7%)297/347 (85.6%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventAA4500
Penile haematomaReproductive system and breast disorders2/347
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/347
Inguinal herniaGastrointestinal disorders1/347
Tendon ruptureInjury, poisoning and procedural complications1/347
Deep vein thrombosisVascular disorders1/347
Acute myocardial infarctionCardiac disorders1/347
Device occlusionGeneral disorders1/347
Fracture of penisInjury, poisoning and procedural complications1/347
NephrolithiasisRenal and urinary disorders1/347
ManiaPsychiatric disorders1/347
Most frequent other events
Most frequent other events
EventAA4500
Penile haematomaReproductive system and breast disorders178/347
Penile painReproductive system and breast disorders120/347
Injection site painGeneral disorders93/347
Penile swellingReproductive system and breast disorders91/347
Injection site haematomaGeneral disorders84/347
Penile haemorrhageReproductive system and breast disorders79/347
Penile oedemaReproductive system and breast disorders49/347
Injection site swellingGeneral disorders40/347
Painful erectionReproductive system and breast disorders19/347

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)AA4500
<=18 years0
Between 18 and 65 years289
>=65 years58
Age, Continuous
Age, Continuous(years)AA4500
Mean56.5 ± 9.0
Sex: Female, Male
Sex: Female, Male(Participants)AA4500
Female0
Male347
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AA4500
Hispanic or Latino22
Not Hispanic or Latino325
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AA4500
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American4
White333
More than one race0
Unknown or Not Reported8
Region of Enrollment
Region of Enrollment(participants)AA4500
France13
United States102
Spain21
Denmark42
Germany41
Italy24
United Kingdom17
New Zealand54
Sweden33
08

Study locations

39 sites
  • Urology Associates Medical Group
    Burbank, California 91505, United States
  • Connecticut Clinical Research Center, LLC
    Middlebury, Connecticut 06762, United States
  • The Urology Center, P.C.
    New Haven, Connecticut 06511, United States
  • South Florida Medical Research
    Aventura, Florida 33180, United States
  • Urology Specialists, S.C.
    Chicago, Illinois 60612, United States
  • Northeast Indiana Research, LLC
    Fort Wayne, Indiana 46825, United States
  • Metropolitan Urology, P.S.C.
    Jeffersonville, Indiana 47130, United States
  • Maimonides Medical Center, Division of Urology
    Brooklyn, New York 11219, United States
  • University Urology Associates
    New York, New York 10016, United States
  • Tristate Urologic Services PSC, Inc./ dba TUG Research
    Cincinnati, Ohio 45212, United States
  • Urologic Consultants of SE PA
    Bala-Cynwyd, Pennsylvania 19004, United States
  • Urology of Virginia-Sentara Medical Group
    Norfolk, Virginia 23502, United States
  • Virginia Urology
    Richmond, Virginia 23235, United States
  • Aarhus Universitiy Hospital, Aalborg Sygehus
    Aalborg, DK-9100, Denmark
  • Frederiksberg Hospital
    Frederiksberg, DK-2000, Denmark
  • Frederikssunds Hospital
    Frederikssund, DK-3600, Denmark
  • Klinik for seksuelle dysfunktioner
    Gentofte, DK-2820, Denmark
  • Centre Hospitalier Edouar Herriot
    Lyon, F-69 437, France
  • Hopital Henri Gabrielle
    Saint Genis Laval, F-69230, France
  • Universitatsklinikum Freiburg, Abteilung Urologie
    Freiburg, DE-79106, Germany
  • Private Practice of Urology/Andrology
    Hamburg, DE-20354, Germany
  • Uro-Onkologische Praxis Dr. von Keitz
    Marburg, DE-35039, Germany
  • Urologische Gemeinschaftspraxis Reutlingen
    Reutlingen, DE-72764, Germany
  • Universitatsklinikum Tubingen
    Tubingen, DE-72096, Germany
  • University of Naples "Federico II"
    Naples, I-80131, Italy
  • Universitiy Tor Vergatat of Rome
    Rome, I-00133, Italy
  • Waitemata Urology Research North Shore Hospital
    Takapuna, Auckland 0622, New Zealand
  • Tauranga Urology Research Ltd.
    Tauranga, Bay of Plenty 3140, New Zealand
  • Primorus Clinical Trials Ltd.
    Christchurch, Canterbury 8011, New Zealand
  • CURT Medical Trials Trust Board Inc.
    Christchurch, Canterbury 8014, New Zealand
  • Cardinal Points Research Ltd.
    Whangarei, Northland 0112, New Zealand
  • Wellington Urology Associates
    Wellington South, Wellington 6021, New Zealand
  • Hospital Clinic de Barcelona
    Barcelona, ES-08036, Spain
  • Hospital La Zarzuela
    Madrid, ES-28043, Spain
  • Specialistmottagningen i urologi
    Goteborg, SE-405 45, Sweden
  • Carlshamns Specialistklinik
    Karlshamn, SE-374 35, Sweden
  • Akademiska Sjukhuse
    Uppsala, SE-751 85, Sweden
  • St. Peter's Andrology Centre
    London, W1G 6BJ, United Kingdom
  • Sunderland Royal Hospital
    Sunderland, SR4 &TP, United Kingdom
09

References and documents

Publications

  • Levine LA, Cuzin B, Mark S, Gelbard MK, Jones NA, Liu G, Kaufman GJ, Tursi JP, Ralph DJ. Clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with Peyronie's disease: a phase 3 open-label study. J Sex Med. 2015 Jan;12(1):248-58. doi: 10.1111/jsm.12731. Epub 2014 Nov 12. PubMed 25388099 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2015, 2 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2010
First posted
Nov 18, 2010
Start
Nov 2010
Primary completionActual
Aug 2012
CompletionActual
Aug 2012
Results first posted
Apr 15, 2015
Last update
Oct 5, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 5, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01243411
Responsible party
Sponsor
First posted
Nov 18, 2010
Start date
Nov 2010
Primary completion
Aug 2012
Completion
Aug 2012
Results posted
Apr 15, 2015
Last update
Oct 5, 2017

Study contacts

Gregory J. Kaufman, MD
study director · Auxilium Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Microbial Collagenase

Start the discussion